Patents Issued in September 14, 2004
-
Patent number: 6790818Abstract: The present invention provide a composition suitable for use as a foaming hand dishwashing composition comprising a hydrophobic polymer having molecular weight of at least 500 and comprising butylene oxide moieties with the proviso that the composition does not comprise greater than 5% by weight of the composition of builder.Type: GrantFiled: March 20, 2002Date of Patent: September 14, 2004Assignee: Procter & Gamble CompanyInventors: Patrice Mark Luc Borgonjon, Baptiste Pommiers, Mark Robert Sivik, Jean-Francois Bodet
-
Patent number: 6790819Abstract: The present invention relates to fabric care methods for restoring and/or rejuvenating color of worn, faded fabric, by applying to said fabric a fabric color care composition which comprises: water soluble and/or water dispersible polymers; surfactant capable of forming a bilayer structure; and mixtures thereof. Optionally, the composition can contain other ingredients to provide additionally fabric care benefits, and/or to improve performance and formulability. The composition is preferably applied as small particle size droplets, especially from spray container that preferably are in association with a set of instructions for use.Type: GrantFiled: November 15, 2001Date of Patent: September 14, 2004Assignee: The Procter & Gamble CompanyInventors: Toan Trinh, Mary Vijayarani Barnabas, Eugene Paul Gosselink, John William Smith, Helen Bernardo Tordil, Robb Richard Gardner, Timothy Woodrow Coffindaffer
-
Patent number: 6790820Abstract: The present invention provides compositions comprising an HFC component and a non-HFC component consisting essentially of methanol, having boiling points that are unexpectedly low and relatively constant, and uses thereof.Type: GrantFiled: June 3, 2002Date of Patent: September 14, 2004Assignee: Honeywell International, Inc.Inventors: Mary C. Bogdan, Gary M. Knopeck, Hang T. Pham, Rajiv R. Singh, Kane D. Cook
-
Patent number: 6790821Abstract: A process for preparing coated detergent granules in a fluidized bed is provided. The fluidized bed is operated at a flux number of at least about 3.5 and/or a Stokes Number of greater than 1.0. Upon drying, the resultant detergent particles have improved appearance and flow properties and may be packaged and sold as a detergent material or mixed with various other detergent ingredients to provide a fully formulated detergent composition.Type: GrantFiled: November 30, 2001Date of Patent: September 14, 2004Assignee: The Procter & Gamble CompanyInventors: Matthew Israel Wasserman, Mark William Ridyard, Scott William Capeci, Wayne Edward Beimesch, Paul R Mort, III
-
Patent number: 6790822Abstract: The present invention relates to a laundry detergent composition comprising an anionically modified cellulose (AMC); and a cationic metal ion. The molar ratio of the anionically modified group of the AMC to the cationic metal ion is preferably from about 50:1 to about 1:50. The laundry detergent composition containing such materials maintain a good fabric appearance, such as better pill/fuzz prevention and color maintenance.Type: GrantFiled: July 13, 2001Date of Patent: September 14, 2004Assignee: The Proctor & Gamble CompanyInventors: Hajime Baba, Susumu Murata, Jiping Wang
-
Patent number: 6790823Abstract: Methods and compositions for the prevention and treatment of cardiovascular disease is described. Administration of osteoprotegerin (OPG) in a pharmaceutical composition prevents and treats atherosclerosis and associated cardiovascular diseases.Type: GrantFiled: April 23, 1998Date of Patent: September 14, 2004Assignee: Amgen Inc.Inventors: Scott Simonet, Ildiko Sarosi
-
Patent number: 6790824Abstract: The present invention relates to a pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines, wherein at least one of said cytokines is BMP, GDF, TGF-&bgr; or GDNF.Type: GrantFiled: March 17, 2000Date of Patent: September 14, 2004Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Klaus Unsicker, Jens Pohl, Michael Paulista, Rolf Bechtold
-
Patent number: 6790825Abstract: Secretin and secretin compositions are used for the treatment of autism and other neurological, behavioral and immunological disorders. The method includes administering an effective amount of secretin, such as Secretin-Ferring, to a patient. In one example, 2 clinical units (CU) of Secretin-Ferring was dissolved in a 7.5 ml solution of sodium chloride and was intravenously injected over 1 minute. In another example, secretin was administered transdermally by applying dimethyl sulfoxide (DMSO) to the patients skin and rubbing about 15 CU of Secretin-Ferring into the DMSO. Other methods and compositions for administering the effective amount of secretin include other transdermal carrier substances, such as gels, lotions, or patches; oral carriers, such as tablets, capsules, or lozenges; inhalation through the nose or mouth (e.g., as an aerosol); suppository forms of secretin and secretin compositions; and using acoustic waves to cause the secretin to penetrate the skin.Type: GrantFiled: March 5, 2001Date of Patent: September 14, 2004Assignee: Repligen CorporationInventors: Victoria Beck, Bernard Rimland
-
Patent number: 6790826Abstract: Disclosed are human haemopoietic maturation factor polypeptides and DNA (RNA) encoding such haemopoietic maturation factor polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and for using such polypeptides for treating leukemia, auto-immune diseases and blood related disorders. Antagonists against such polypeptides and their use as a therapeutic to prevent expansion of T-cell populations are also disclosed. Diagnostic assays are also disclosed to detect both the presence of mutations in the haemopoietic maturation factor nucleic acid sequences and altered levels of the protein.Type: GrantFiled: December 7, 2001Date of Patent: September 14, 2004Assignee: Human Genome Sciences, Inc.Inventors: Ewen F. Kirkness, Mark D. Adams, Henrik Olsen, Craig A. Rosen
-
Patent number: 6790827Abstract: The present invention relates to bioconjugates and the delivery of bioactive agents which are preferably targeted for site-specific release in cells, tissues or organs. More particularly, this invention relates to bioconjugates which comprise a bioactive agent and an organocobalt complex. The bioactive agent is covalently bonded directly or indirectly to the cobalt atom of the organocobalt complex. The bioactive agent is released from the bioconjugate by the cleavage of the covalent bond between the bioactive agent and the cobalt atom in the organocobalt complex. The cleavage may occur as a result of normal displacement by cellular nucleophiles or enzymatic action, but is preferably caused to occur selectively as a predetermined release site by application of an external signal. The external signal may be light or photoexcitation, i.e. photolysis, or it may be ultrasound, i.e. sonolysis.Type: GrantFiled: October 22, 2001Date of Patent: September 14, 2004Assignee: University of Utah Research FoundationInventors: Charles B. Grissom, Frederick G. West, W. Allen Howard, Jr.
-
Patent number: 6790828Abstract: The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.Type: GrantFiled: May 14, 2003Date of Patent: September 14, 2004Assignee: Schering AktiengesellschaftInventors: David Light, Michael John Morser, Mariko Nagashima
-
Patent number: 6790829Abstract: Several cyclic decapeptides having antibiotic activity are disclosed. The decapeptides are active against both gram positive and gram negative bacteria.Type: GrantFiled: September 29, 1998Date of Patent: September 14, 2004Assignees: SeaTek Marine Biotechnology, Inc., University of British ColumbiaInventors: Michael T. Kelly, Raymond J. Andersen, Jeff Gerard
-
Patent number: 6790830Abstract: The present invention discloses a hair growth promoting agent comprising a cyclosporin derivative as an active ingredient, and more particularly, a hair growth promoting agent comprising a cyclosporin A derivative substituted in the 3-position as an active ingredient.Type: GrantFiled: May 9, 2002Date of Patent: September 14, 2004Assignee: LG Household & Health Care Ltd.Inventors: Sang-Nyun Kim, Ho-Jeong Ahn, Chang-Woo Lee, Min-Ho Lee, Jung-Hun Kim, Jong-Il Kim, Seung-Jin Kim, Ho-Song Cho, Heon-Sik Lee, Hyung-Jin Kim
-
Patent number: 6790831Abstract: The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.Type: GrantFiled: March 2, 2001Date of Patent: September 14, 2004Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose
-
Patent number: 6790832Abstract: A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.Type: GrantFiled: April 23, 2002Date of Patent: September 14, 2004Assignee: Aventis Behring GmbHInventors: Jürgen Römisch, Gerhard Dickneite, Peter Gronski, Bernhard Vohwinkel, Harald Stauss, Elaine Gray, Pauline Sxouter, Stephen Poole
-
Patent number: 6790833Abstract: The present invention discloses peptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7. The peptides are between 8 and 20 amino acids in length and have a net positive charge. The peptides are obtained from the C-terminus of the MUC7D1 protein. These peptides are useful as antifungal and antibacterial agents. A method of using these peptides as antifungal and antibacterial agents is also disclosed.Type: GrantFiled: August 8, 2002Date of Patent: September 14, 2004Assignee: The Research Foundation of the State University of New YorkInventor: Libuse Bobek
-
Patent number: 6790834Abstract: Compounds of formula I are disclosed wherein R4 is an ester or thioester group, and R, R1, R2, and R3 are as defined in the specification are inhibitors of rapidly dividing tumor cells.Type: GrantFiled: February 28, 2000Date of Patent: September 14, 2004Assignee: British Biotech Pharmaceuticals, Ltd.Inventors: Lindsey Ann Pearson, Andrew Paul Ayscough, Philip Huxley, Alan Drummond
-
Patent number: 6790835Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.Type: GrantFiled: June 5, 2003Date of Patent: September 14, 2004Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yao-Ling Qiu, Ly Tam Phan, Tongzhu Liu, Zhigang Chen, Yat Sun Or
-
Patent number: 6790836Abstract: A process for preparing indolopyrrolocarbazole derivatives [I] by trating a compound [V] with a base in an inert solvent to prepare a compound [IV], reacting the compound [IV] with a compound [III]to prepare a compound [II], and deblocking the compound [II]; intermediates [II], [III] and [IV]; and a process for preparing compounds [III]: [wherein Y1 is hydrogen, C1-4 alkyl, phenyl, benzyloxymethyl, or aralkyl; R1, R2, R3, R4, R5, and R6 are each independently a hydroxyl-protecting group; R7 and R8 are each independently hydrogen or a hydroxyl-protecting group; and X is an acid molecule]. The above process is a safe and easy industrial process for preparing indolopyrrolocarbazole derivatives [1] useful as antitumor agents.Type: GrantFiled: August 6, 2002Date of Patent: September 14, 2004Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Shouichi Hiraga, Masashi Kawasaki, Atsushi Akao, Asayuki Kamatani, Masayuki Hagiwara, Toshiaki Mase, Fumio Nakano
-
Patent number: 6790837Abstract: A liquid formulation comprising ribavirin having a longer shelf life and improved taste is disclosed.Type: GrantFiled: October 31, 2002Date of Patent: September 14, 2004Assignee: Schering CorporationInventors: Susan K. Heimbecher, Joel A. Sequeira
-
Patent number: 6790838Abstract: Combinations and methods for inducing a semi-synchronous wave of liver cell proliferation in vivo and combinations and methods for inducing a semi-synchronous wave of liver cell proliferation and achieving transduction of proliferating liver cells in vivo are disclosed.Type: GrantFiled: January 24, 2001Date of Patent: September 14, 2004Assignees: Amgen, Inc., Imperial College Innovations LTDInventors: Malcolm R. Alison, Charles Coutelle, Stuart J. Forbes, Humphrey J. F. Hodgson, Ildiko Sarosi, Michael Themis
-
Patent number: 6790839Abstract: The present invention relates to a method of inducing proliferation of bone marrow cells in a subject, compromising administering to the subject an effective amount of an adenosine A1 receptor agonist. The present invention further relates to a method for preventing reduction in level of leukocytes in a subject as a result of a treatment comprising administering to the individual an effective amount of an adenosine A1 receptor agonist. In addition, the invention relates to a method of treatment of an individual comprising administering to the subject a therapeutic drug in combination with an adenosine A1 receptor agonist.Type: GrantFiled: February 14, 2001Date of Patent: September 14, 2004Assignee: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Ilan Cohn
-
Patent number: 6790840Abstract: A hydrogel composition and methods of preparing and using the same are disclosed. The hydrogel composition comprises an oxidized polysaccharide, and a cross-linker having at least two functional cross-linking groups. The cross-linker reversibly cross-links the polysaccharide and is provided in an amount to provide dangling cross-linkers. The method of preparing a hydrogel comprises the steps of providing an oxidized polysaccharide, and providing a cross-linker having at least two functional cross-linking groups. The cross-linker is mixed with the polysaccharide at a concentration of the cross-linker sufficient to form a hydrogel wherein the cross-linker reversibly cross-links the polysaccharide and has dangling cross-linkers. The hydrogels are useful, for example, for tissue engineering, cell transplantation and drug delivery applications.Type: GrantFiled: November 27, 2000Date of Patent: September 14, 2004Assignee: The Regents of the University of MichiganInventors: Kuen Yong Lee, David J. Mooney
-
Patent number: 6790841Abstract: Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of 6-aminopurine (adenine), 2,6-diaminopurine, 2-amino-6-azidopurine, 2-amino-6-cyclopropylaminopurine, 6-hydroxypurine (hypoxanthine), 2-amino-6-halo substituted purines, 2-amino-6-alkoxy substituted purines, 2-amino-6-hydroxypurine (guanine), 3-deazapurines, 7-deaza-purines, 8-azapurines, cytosine, 5-halo substituted cytosines, 5-alkyl substituted cytosines, thymine, uracil and 6-azapyrimidines; X is O; and, R1 and R2 are alkyl or aryl groups. The compounds of the present invention also include the R- and S-enantiomers of the above compounds. The R1X and/or R2X can also be amino acid residues with X as NH.Type: GrantFiled: January 14, 2002Date of Patent: September 14, 2004Assignees: Wayne State University, The Regents of the University of MichiganInventors: Jiri Zemlicka, Yao-Ling Qiu, John C. Drach, Roger G. Ptak
-
Patent number: 6790842Abstract: This invention describes a 11&bgr;-long-chain-substituted estratriene of general formula (I), in which R11 is a long-chain radical that has a nitrogen atom and optionally a sulfur atom, which in addition can be functionalized in the terminal position with a perfluoroalkyl group or an optionally substituted arly radical. The compound can have antiestrogenic or tissue-selective estrogenic properties and be suitable for the production of pharmaceutical agents.Type: GrantFiled: May 7, 2002Date of Patent: September 14, 2004Assignee: Schering AktiengesellschaftInventors: Rolf Bohlmann, Nikolaus Heinrich, Jorg Kroll, Gerhard Sauer, Karl-Heinrich Fritzemeier, Christa Hegele-Hartung, Jens Hoffmann, Rosemarie Lichtner, Ludwig Zorn
-
Patent number: 6790843Abstract: The invention relates to new C-19-halogen-substituted steroids of the androst-9(11)-ene series, namely 17&bgr;-hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula (I) and process for their production. In addition, the use of new radiohalogen-labeled compounds of Formula (I) as radiopharmeceutical agents is the subject of the invention as well as the use of non-labeled compounds of Formula (I) as starting products for the production of new biologically active 5&bgr;-substituted androst-9(11)-enes of general formula (II) and the new 6&bgr;,19-cycloandrostadienes of Formula (III) as well as processes for their production and their use.Type: GrantFiled: July 2, 2002Date of Patent: September 14, 2004Assignee: Schering AGInventors: Gunter Neef, Roland Golde, Karl-Heinrich Fritzemeier
-
Patent number: 6790844Abstract: Condensed pyridine compounds represented by formula (I): wherein: R1 and R3 are, independently, hydrogen, halogen, lower alkyl, or lower alkoxy; R2 represents an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having; serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.Type: GrantFiled: May 11, 2001Date of Patent: September 14, 2004Assignee: Eisai Co., LtdInventors: Kohshi Ueno, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Noritaka Kitazawa, Keiko Takahashi, Noboru Yamamoto, Yuichi Suzuki, Manabu Matsunaga, Atsuhiko Kubota
-
Patent number: 6790845Abstract: This invention relates generally to a novel class of fused heterocyclic compounds of the Formula (I) or Formula (II): or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.Type: GrantFiled: April 8, 2002Date of Patent: September 14, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Irina C. Jacobson, Mimi L. Quan, Ruth R. Wexler
-
Patent number: 6790846Abstract: Isoxazolone compounds having the generic structure: are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiter's syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.Type: GrantFiled: May 7, 2002Date of Patent: September 14, 2004Assignee: The Procter & Gamble CompanyInventors: Michael Philip Clark, Jane Far-Jine Djung, Steven Karl Laughlin, Joshua Spector Tullis, Michael George Natchus, Biswanath De
-
Patent number: 6790847Abstract: The present invention relates to a drug composition containing the non-sedating H1 antihistamines cetirizine, loratadine, mixtures or pharmaceutically acceptable salts thereof for topical application in the form of a gel.Type: GrantFiled: December 30, 2002Date of Patent: September 14, 2004Assignee: Oramon Arzneimittel GmbHInventor: Hatto Walch
-
Patent number: 6790848Abstract: This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I: wherein R3 is SO2—Ar, Ar is aryl or heteroaryl; and R1, R2, R4 and R5 are as defined herein; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.Type: GrantFiled: June 14, 2002Date of Patent: September 14, 2004Assignee: Syntex (U.S.A.) LLCInventors: Andrew John Briggs, Robin Douglas Clark, Ralph New Harris, III, David Bruce Repke, Douglas Leslie Wren
-
Patent number: 6790849Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.Type: GrantFiled: March 26, 2002Date of Patent: September 14, 2004Assignee: Sepracor Inc.Inventor: Paul D. Rubin
-
Patent number: 6790850Abstract: The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: March 29, 2002Date of Patent: September 14, 2004Assignee: AstraZeneca UK LimitedInventors: Paul Andrew Willis, Roger Victor Bonnert, Simon Fraser Hunt, Iain Alistair Stewart Walters
-
Patent number: 6790851Abstract: The invention comprises a method of combating phytopathogenic diseases on crop plants which comprises applying to the crop plants or the locus thereof being infested with said phytopathogenic disease an effective amount of a combination of a) a benzophenone of formula I wherein R1 is methoxy, methyl, hydroxy, acetoxy or pivaloyloxy, R2 is C1-C4alkoxy or 2-halogenbenzyloxy, R3 is C1-C4alkoxy, R4 is C1-C4alkyl, halogen or trifluoromethyl, and R5 is hydrogen, halogen, C1-C4alkoxy, trifluoromethyl or nitro; in association with b) the strobilurin of formula II and a composition comprising fungicidally effective amounts of components I and II and a composition.Type: GrantFiled: March 11, 2003Date of Patent: September 14, 2004Assignee: Syngenta Crop Protection, Inc.Inventor: Neil Leadbitter
-
Patent number: 6790852Abstract: The invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and related diseases.Type: GrantFiled: April 7, 2003Date of Patent: September 14, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Michael Brandt, Georg Fertig, Hans-Willi Krell, Thomas von Hirschheydt, Edgar Voss
-
Patent number: 6790853Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.Type: GrantFiled: March 31, 2003Date of Patent: September 14, 2004Assignee: Schering AGInventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
-
Patent number: 6790854Abstract: A substance having affinity for an opioid &dgr; receptor, which is represented by the following general formula (I): wherein, X represents a group of the general formula: —CO—N(R5)(R6) (II) and the like, n represents 1 to 3, R1 and R2 represent a hydrogen atom, a halogen atom, a lower alkyl group and the like, R3 represents a hydrogen atom, a halogen atom, a lower alkyl group and the like, R4 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, R5 to R12 represent a hydrogen atom, a lower alkyl group and the like, and R3 and R4, R5 and R6, R7 or R8 and R9 and R10 may bind to each other to form a cyclic structure, and a medicament useful for preventive and/or therapeutic treatment of central nervous system diseases and peripheral nervous system diseases comprising the substance as an active ingredient.Type: GrantFiled: March 13, 2003Date of Patent: September 14, 2004Assignee: Meiji Seika Kaisha, Ltd.Inventors: Masaki Tsushima, Kaori Tadauchi, Kenji Asai, Naoko Miike, Toshiaki Kudo
-
Patent number: 6790855Abstract: Many chemical and pharmaceutical compositions are known to produce antinociceptive effects that are helpful in relieving pain and inflammation. Both opioids and local anesthetics serve an important function in providing peripheral pain relief. Topical administration of pain-relieving drugs to the periphery offers important advantages over systemic or local, non-topical administration. The present invention provides topical pharmaceutical compositions, formulated with at least one local anesthetic and at least one opioid analgesic in a topical excipient. The present invention also provides methods for relieving pain in a subject through topical administration of the pharmaceutical composition in an amount and a duration sufficient to synergistically potentiate an antinociceptive response. Synergistic potentiation of analgesia through topical administration of a local anesthetic/opioid pharmaceutical composition provides a new and improved approach to peripheral pain management.Type: GrantFiled: October 11, 2001Date of Patent: September 14, 2004Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Gavril Pasternak, Yuri Kolesnikov
-
Patent number: 6790856Abstract: Flourenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.Type: GrantFiled: January 2, 2003Date of Patent: September 14, 2004Assignee: Boehringer Ingelheim Pharma KGInventors: Sabine Germeyer, Helmut Meissner, Gerd Morschhaeuser, Sabine Pestel, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck
-
Patent number: 6790857Abstract: This invention provides a method for preparing a benzoylecgonine composition comprising the steps of: (a) contacting benzoylmethylecgonine and propylene glycol in the presence or absence of water to form a reaction mixture; (b) maintaining the reaction mixture at a temperature between about 50° and 100° C.; and (c) subsequently or simultaneously removing water from the reaction mixture. This invention also provides novel benzoylecgonine and methods for producing them.Type: GrantFiled: November 13, 2002Date of Patent: September 14, 2004Assignee: Entropin, Inc.Inventor: Nicholas James Archer
-
Patent number: 6790858Abstract: The present invention relates to a compound of formula (I): where R1-R6, W, X, and Y are defined herein, a composition includung the compound of formula (I), and a method for, e.g., male birth control, including administering an effective amount of a compound of formula (I) to a patient in need thereof.Type: GrantFiled: February 21, 2002Date of Patent: September 14, 2004Assignee: Zentaris AGInventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Roland Kühne, Eckhard Guenther, Emmanuel Polymeropoulos, Antonius M. Ter Laak
-
Patent number: 6790859Abstract: The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.Type: GrantFiled: January 21, 2003Date of Patent: September 14, 2004Assignee: Alteon IncorporatedInventors: Dilip R. Wagle, Sheng-Ding Fang, Taikyun Rho, John J. Egan, Sara Vasan, Peter Ulrich, Anthony Cerami
-
Patent number: 6790860Abstract: The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.Type: GrantFiled: February 25, 2003Date of Patent: September 14, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Johannes Aebi, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Ulrike Obst, Hans Peter Wessel
-
Patent number: 6790861Abstract: The invention relates to the use of certain acid donors as stabilizers in pharmaceutical compositions, and to the stabilized pharmaceutical compositions resulting therefrom.Type: GrantFiled: May 23, 2003Date of Patent: September 14, 2004Assignee: Novartis AGInventors: Richard V. Vivilecchia, Bruce A. Ross
-
Patent number: 6790862Abstract: This invention relates to a bioactive compound and to compositions which contain it. The invention further relates to methods of microtubule stabilization. In particular, it relates to a compound which has cytotoxic properties and which therefore has utility in inter alia anti-tumor treatments.Type: GrantFiled: February 11, 2002Date of Patent: September 14, 2004Assignee: Victoria Link LimitedInventors: Peter T. Northcote, John H. Miller, Kylie A. Hood, Lyndon M. West
-
Patent number: 6790863Abstract: This invention comprises compositions containing dihydroartemisinin and dihydroartemisitene dimers with activity as anticancer agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor agents, one that has shown promising activity against solid tumors, and with a pattern of selectivity that suggests a possible new mechanism of action.Type: GrantFiled: October 15, 2002Date of Patent: September 14, 2004Assignee: University of MississippiInventors: Mahmoud A. ElSohly, Samir A. Ross, Ahmed M. Galal
-
Patent number: 6790864Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.Type: GrantFiled: October 22, 2002Date of Patent: September 14, 2004Assignee: NitroMed, Inc.Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
-
Patent number: 6790865Abstract: The present invention provides novel 2-methylpropionic acid derivatives represented by the general formula: (wherein R1 represents a hydrogen atom, a lower alkyl group or an aralkyl group; R2 represents a hydrogen atom, a lower alkyl group or a halogen atom; A represents an oxygen atom or an imino group; the carbon atom marked with (R) represents a carbon atom in R configuration; and the carbon atom marked with (S) represents a carbon atom in S configuration) and pharmaceutically acceptable salts thereof, which have excellent &bgr;3-adrenoceptor stimulating effects and are useful as agents for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of the biliary tract.Type: GrantFiled: February 5, 2003Date of Patent: September 14, 2004Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Tetsuro Tamai, Nobuyuki Tanaka, Harunobu Mukaiyama, Akihito Hirabayashi, Hideyuki Muranaka, Masaaki Sato, Masuo Akahane
-
Patent number: 6790866Abstract: The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is —COR1, —CH═CH—COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4). The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.Type: GrantFiled: July 30, 2002Date of Patent: September 14, 2004Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Shuichi Ohuchida, Yuuki Nagao
-
Patent number: 6790867Abstract: Novel formulations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, with a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol are disclosed. Methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease and swine respiratory disease, are also disclosed.Type: GrantFiled: January 24, 2003Date of Patent: September 14, 2004Assignee: Schering-Plough Animal Health CorporationInventors: Raul E. Kohan, Kanwal J. Varma, Robert D. Simmons, Abu Huq, Keith A. Freehauf